Topic Hub
15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 15 of 15 clinical reviews.
Can Wegovy (semaglutide 2.4 mg) treat alcohol use disorder? Review the clinical trial evidence, off-label prescribing rationale, GRADE quality rating, and monitoring requirements for patients and clinicians.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) is being studied off-label for alcohol use disorder. This clinician-reviewed guide covers the trial data, mechanistic rationale, GRADE-level evidence, real risks, and how to talk to your prescriber.
Read clinical reviewCan semaglutide 2.4 mg (Wegovy) treat alcohol use disorder? Review the preclinical and early clinical evidence, proposed dosing protocols, and what physicians should know before prescribing off-label.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) is not FDA-approved for alcohol use disorder, but emerging preclinical and observational data suggest GLP-1 receptor agonists may reduce alcohol intake. Here is what clinicians and patients need to know.
Read clinical reviewA clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including dosing protocols, trial evidence, safety data, and what patients should discuss with their provider.
Read clinical reviewA clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including trial data, risk-benefit analysis, and practical prescribing considerations.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) is being used off-label for binge eating disorder. Review the clinical evidence, monitoring protocols, and what patients and clinicians should track during treatment.
Read clinical reviewAn evidence-based review of semaglutide 2.4 mg (Wegovy) for binge eating disorder, including off-label status, clinical trial data, GRADE-level evidence, and what clinicians and patients need to know before starting treatment.
Read clinical reviewA clinical evidence summary of semaglutide 2.4 mg (Wegovy) for cardiovascular prevention, covering SELECT trial data, FDA-approved indications, off-label context, and GRADE-level evidence ratings.
Read clinical reviewWegovy (semaglutide 2.4 mg) now has FDA-approved cardiovascular data from SELECT, but using it purely for CV prevention without a weight-loss indication remains off-label. Here is what the evidence actually shows, what guidelines say, and how clinicians should weigh the tradeoffs.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) reduces major cardiovascular events by 20% in the SELECT trial. Learn when CV prevention use is on-label vs. off-label, the dosing protocol, evidence grade, and what clinicians should consider.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) shows strong cardiovascular risk reduction in SELECT trial data. Learn the off-label evidence, monitoring requirements, and clinical considerations for using Wegovy beyond weight management.
Read clinical reviewA clinical evidence review of semaglutide 2.4 mg (Wegovy) for nonalcoholic steatohepatitis (NASH/MASH), covering phase 2 and phase 3 trial data, mechanism of action, GRADE-level assessment, and practical prescribing considerations.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) is not FDA-approved for NASH. Here is what the phase 2 trial data shows about NASH resolution, the risks of off-label use, and how clinicians weigh the tradeoffs.
Read clinical reviewSemaglutide 2.4 mg (Wegovy) is used off-label for NASH/MASH. Learn the clinical trial evidence, monitoring schedule, liver enzyme targets, and what your provider should track.
Read clinical review